秦息痛联合重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗缓解期类风湿关节炎的临床效果  

Clinical effect of Qinxitong combined with recombinant human tumor necrosis factor receptor-Fc fusion protein in the treatment of remission rheumatoid arthritis

作　　者：王瑞松[1] 李锐[1] 张俊莉 李娟[1] 周威 刘丹[2] 黄小强 贠丹丹 WANG Ruisong;LI Rui;ZHANG Junli;LI Juan;ZHOU Wei;LIU Dan;HUANG Xiaoqiang;YUN Dandan(Xi'an No.5 Hospital/Affiliated Hospital of Integrated Chinese and Western Medicine of Shaanxi University of Chinese Medicine,Xi'an 710082;the First Affiliated Hospital of Xi'an Medical University,Xi'an 710021,China)

机构地区：[1]西安市第五医院/陕西中医药大学附属中西医结合医院,陕西西安710082 [2]西安医学院第一附属医院,陕西西安710021

出　　处：《临床医学研究与实践》2021年第23期42-45,共4页Clinical Research and Practice

基　　金：西安市卫生健康委员会项目(No.2020ms06);2020年卫生科研人才项目(No.2020yb17)。

摘　　要：目的探讨秦息痛联合重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗缓解期类风湿关节炎(RA)的临床效果。方法选取2019年12月至2020年10月我院收治的82例缓解期RA患者作为研究对象,将其随机分为对照组(n=41)和治疗组(n=41)。对照组给予重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗,治疗组给予半剂量重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合秦息痛治疗。比较两组的治疗效果。结果治疗组的治疗总有效率为97.56%,高于对照组的78.05%(P<0.05)。治疗后,两组的CRP、RF、IgG水平及ESR均较治疗前降低,且治疗组低于对照组(P<0.05)。治疗后,两组的WBC及AST、ALT、BUN、Cr水平均较治疗前降低,且治疗组低于对照组(P<0.05)。治疗4、8周后,两组的DAS28评分均较治疗前降低(P<0.05)。两组不良反应总发生率无显著差异(P>0.05)。结论秦息痛联合重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗缓解期RA的效果显著,可缓解患者的临床症状,降低CRP、RF、IgG水平及ESR,且不增加不良反应。Objective To investigate the clinical effect of Qinxitong combined with recombinant human tumor necrosis factor receptor-Fc fusion protein in the treatment of remission rheumatoid arthritis(RA).Methods A total of 82 patients with remission RA admitted in our hospital from December 2019 to October 2020 were randomly divided into control group(n=41)and treatment group(n=41).The control group was treated with recombinant human tumor necrosis factor receptor-Fc fusion protein,and the treatment group was treated with half dose recombinant human tumor necrosis factor receptor-Fc fusion protein combined with Qinxitong.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the treatment group was 97.56%,which was higher than 78.05%in the control group(P<0.05).After treatment,CRP,RF,IgG levels and ESR of the two groups were lower than those before treatment,and those in the treatment group were lower than the control group(P<0.05).After treatment,WBC,AST,ALT,BUN and Cr levels in the two groups were lower than those before treatment,and those in the treatment group were lower than the control group(P<0.05).After 4 and 8 weeks of treatment,the DAS28 scores of the two groups were lower than those before treatment(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Qinxitong combined with recombinant human tumor necrosis factor receptor-Fc fusion protein in the treatment of remission RA has a significant effect.It can relieve the clinical symptoms,reduce the CRP,RF,IgG levels and ESR,and does not increase the adverse reactions.

关 键 词：类风湿性关节炎 秦息痛 重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 缓解期 

分 类 号：R593.22[医药卫生—内科学]